Immutep Limited

ASX Code



Pharmaceuticals- Biotechnology & Life Sciences

Investor Centre





Global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or "LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases. IMM's objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.


Immutep (ASX:IMM) - Webinar Presentation
Stocks of the Hour: Whispir, QX Resources, Immutep, Magnis Energy Tech
Immutep makes headway in late-stage trials
Immutep (ASX:IMM) - Webinar Presentation
Immutep (ASX: IMM) - Webinar Presentation
Immutep (ASX:IMM) granted Japanese patent for IMP761
Immutep (ASX:IMM) TACTI-002 data presented at ASCO 2022
Immutep Limited (ASX:IMM) Investor Presentation
How Immutep Treats Head & Neck Cancer
Latest from Immutep (ASX: IMM) on LAG-3 and 2022 Outlook
Immutep Taking the Fight to Cancer
Immutep Leading the development of immunotherapy for cancer and autoimmune diseases
Institutions Support Immutep Capital Raising
Immutep: A leader in a league alongside global Pharma giants
Immutep: fighting the good fight
Investors Are Listening As Immutep Eyes Revolutionary Cancer Treatments
Australian Ethical On Emerging Biotech Company Immutep (ASX:IMM)


Efti a highly sought after compound for mono & combo Cancer treatment
A Truly Undervalued Company